The prediction and prevention of Alzheimer's disease - Towards a research agenda

Journal of Psychiatry and Neuroscience

Volumn 24, Issue 5, 1999, Pages 413-430

  Van Reekum, Robert ^a,b   Simard, Martine ^a   Cohen, Tammy ^b  

^a Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^b BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; CONFERENCE PAPER; DATA ANALYSIS; HIGH RISK POPULATION; HUMAN; MEDICAL RESEARCH; RISK ASSESSMENT;

AGED; ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; RISK FACTORS;

EID: 0033386419     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (128)

1. Black SE. Alzheimer's: update on new drug treatments. Can J Contin Med Educ 1994;6(11):69-82.
2. Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications [review]. Med Clin North Am 1994;78(4):911-34.
3. van Reekum R, Black SE, Conn D, Clarke D. Cognition-enhancing drugs in dementia: a guide to the near future. Can J Psychiatry 1997;42(Suppl 1):35S-50S.
4. Wertheimer J. Clinical assessment of cerebro-active drugs. In: Fitten LJ, editor. Facts and research in gerontology series IV: Dementia and cognitive impairments. New York: Springer Publishers; 1994. p. 161-70.
5. Davis RE, Doyle PD, Carroll RT, Emmerling MR, Jaen J. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering? [review]. Arzneimittelforschung 1995;45(3A):425-31.
6. Thai LJ, Carta A, Doody R, Leber P, Mohs R, Schneider L, et al. Prevention protocols for Alzheimer disease. Position paper from the international harmonization of dementia drug guidelines. Alzheimer Dis Assoc Disord 1997;11(3):46-9.
7. Green RC, Clarke VC, Thompson NJ, Woodard JL, Letz R. Early detection of Alzheimer disease: methods, markers, and misgivings. Alzheimer Dis Assoc Disord 1997;11(5 suppl):1S-5S.
8. Canadian Study of Health and Aging. The Canadian study of health and aging: study methods and prevalence of dementia in Canada. Can Med Assoc J 1994;150:899-913.
9. Bachman DL, Wolf PA, Linn RT, Knoefel JE, Cobb JL, Belanger AJ, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham study. Neurology 1993;43:515-9.
10. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-9.
11. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheiemer's disease in late onset families. Science 1993;261:921-3.
12. Evans DE, Beckett LA, Field TS, Feng L, Albert MS, Bennett DA, et al. Apolipoprotein E ε4 and incidence of Alzheimer disease in a community population of older persons. JAMA 1997;277:822-4.
13. De Leon MJ, Golomb AE, Convit A, Tarshish CY, McRae T, De Santi S, et al. The radiologic prediction of Alzheimer's disease: the atrophic hippocampal formation. Am J Neuroradiol 1993;14: 897-906.
14. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease: a longitudinal MRI study. Brain 1996;119(Pt 6):2001-7.
15. Doraiswamy MP, Charles CH, Krishnan RRK. Prediction of cognitive decline in early Alzheimer's disease. Lancet 1998;352:1678.
16. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for alipoprotein E. N Engl J Med 1996;334:752-8.
17. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44(1):17-26.
18. van Duijn CM, Hofman A. Risk factors for Alzheimer's disease: the eurodem collaborative re-analysis of case-control studies. Neuroepidemiology 1992;11(1):106-13.
19. Canadian Study of Health and Aging. The Canadian study of health and aging: risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-80.
20. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997;48(7 suppl):27S-35S.
21. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-95.
22. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;51:787-98.
23. Prince M, Rabe-Hesketh S, Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? An analysis based on data from the MRC treatment trial of hypertension in older adults. Neurology 1998;50:374-9.
24. McGeer PL, Schulzer M, McGeer E. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-32.
25. Marcusson J, Rather M, Kittner B, Rossner M, Smith RJ, Babic T, et al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA285) in patients with dementia according to DSMIII-R. Dement Geriatr Cogn Disord 1997;8:320-8.
26. Giacobini E. Therapy of Alzheimer disease: Symptomatic or neuroprotective? [review]. J Neural Transm 1994;43(1):211-7.
27. Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA, et al. Cerebral amyloid deposition and diffuse plaques in "normal aging": evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996; 46:707-19.
28. Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psychol Monogr 1946;60:1-48.
29. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57(12):1168-74.
30. Persson G, Skoog I. Subclinicai dementia: relevance of cognitive symptoms and signs. J Geriatr Psychiatry Neurol 1992;5:172-8.
31. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793-6.
32. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
33. Hanninen T, Soininen H. Age-associated memory impairment: normal aging or warning of dementia? Drugs Aging 1997;11(6): 480-9.
34. O'Brien JT, Beats B, Hill K, Howard R, Sahakian B, Levy R. Do subjective memory complaints precede dementia? A three-year follow-up of patients with supposed "benign senescent forgetfulness". Inf J Geriatr Psychiatry 1992;7:481-6.
35. Brayne C, Best N, Muir M, Richards SJ, Gill C. Five year incidence and prediction of dementia and cognitive decline in a population sample of women aged 70-79 at baseline. Int J Geriatr Psychiatry 1997;12:1107-18.
36. Flicker C, Flicker C, Ferris SH, Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc 1993a;41:1029-32.
37. Schmand B, Jonker C, Hooijer C, Lindeboom J. Subjective memory complaints may announce dementia. Neurology 1996; 46:121-5.
38. Jorm AF, Christensen H, Korten AE, Henderson AS, Jacomb PA, Mackinnon A. Do cognitive complaints either predict future cognitive decline or reflect past cognitive decline? A longitudinal study of an elderly community sample. Psychol Med 1997;27:91-8.
39. Schofield PW, Marder K, Dooneief G, Jacobs D, Sano M, Stern Y. Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Am J Psychiatry 1997;154:609-15.
40. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 24:1019-25.
41. Benton AL. The visual retention test. New York: Psychological Corp; 1955.
42. McKahn, G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44.
43. Tierney MC, Szalai JP, Snow WG, Fisher MB, Nores A, Nadon G, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661-5.
44. Reisberg B, Ferris S, DeLeon M, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
45. Mattis S. Dementia rating scale: professional manual. Florida: Psychological Assessment Resources; 1973.
46. Taylor EM. The appraisal of children with cerebral deficits. Cambridge: Harvard University Press; 1959.
47. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France; 1964
48. Wechsler D, Stone CP. Wechsler Memory Scale. New York: Psychological Corp; 1973.
49. Howieson DB, Dame A, Camicoli R, Sexton G, Payami H, Kaye JA. Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. J Am Geriatr Soc 1997;45:584-9.
50. Bowen J, Teri L, Kukull W, McCormick W, McCurry SM, Larson EB. Progression to dementia in patients with isolated memory loss. Lancet 1997;349:763-5.
51. Flicker C, Ferris SH, Reisberg B. A two-year longitudinal study of cognitive function in normal aging and Alzheimer's disease. J Geriatr Psychiatry Neurol 1993;6:84-96.
52. Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994; 44:1427-32.
53. Fuld, P, Masur DM, Blau AD, Crystal H, Aronson MK. Object-memory evaluation for prospective detection of dementia in normal functioning elderly: Predictive and normative data. J Clin Exp Neuropsychol 1990;12(40):520-8.
54. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York: Psychological Corporation; 1955.
55. Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL, Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology 1995;45:957-62.
56. Linn, RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Belanger AJ, et al. The "preclinical phase" of probable Alzheimer's disease. Arch Neurol 1995;52: 485-90.
57. Backman L, Small BJ. Influences of cognitive support on episodic remembering: Tracing the process of loss from normal aging to Alzheimer's disease. Psychol Aging 1998;13(2):267-76.
58. Small BJ, Helitz A, Fratiglioni L, Almkvist O, Backman L. Cognitive predictors of incident alzheimer's disease: a prospective longitudinal study. Neuropsychology 1997;11(3):413-20.
59. Dartigues JF, Commenges D, Lettener L, Barbewrger-Gateau P, Gilleron V, Fabrigoule C, et al. Cognitive predictors of dementia in elderly community residents. Neuroepidemiology 1997;16:29-39.
60. Benton A. Manual pour l'application du test de retention visuelle. Applications cliniques et visuelle. Applications cliniques et experimentales, ed 2 fr. Paris: Centre de Psychologie Appliquee; 1965.
61. Fabrigoule C, Rouch I, Taberly A, Letteneur L, Commenges D, Mazaux JM, et al. Cognitive process in preclinical phase of dementia. Brain 1998;121:135-41.
62. Simard M, van Reekum R. Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease. Drugs Aging 1999;14:197-230.
63. Coen RF, Maguire C, Swanwick GR, Kirby M, Burke T, Lawlor BA. Letter and category fluency in Alzheimer's disease: a prognostic indicator of progression? Dementia 1996;7:246-50.
64. Baddeley AD, Bressi S, Della Sala S, Logie R, Spinnler H. The decline of working memory in Alzheimer's disease. Brain 1991;114: 2521-42.
65. Camicioli R, Howieson D, Lehman S, Kaye J. Talking while walking: the effect of a dual task in aging and Alzheimer's disease. Neurology 1997;48:955-8.
66. Diaz-Olavarrieta C, Ostrofsky-Solis F, Garcia de la Cadena C, Rodriguez Y, Alonso E. Neuropsychological changes in subjects at risk of inheriting Alzheimer's disease. Neuroreport 1997;8(11):2449-53.
67. Wells CE. Pseudodementia. Am J Psychiatry 1979;136:895-900.
68. Caine ED. Pseudodementia. Current concepts and future directions. Arch Gen Psychiatry 1981;38:1359-64.
69. Krai VA. The relationship between senile dementia (Alzheimer type) and depression. Can J Psychiatry 1983;28:304-5.
70. Krai VA, Emery OB. Long-term follow-up of depressive pseudodementia of the aged. Can J Psychiatry 1989;34:445-6.
71. Sachdev PS, Smith JS, Angus-Lepan H, Rodriguez P. Pseudodementia twelve years on. J Neurol Neurosurg Psychiatry 1990;53:254-9.
72. Reding M, Haycox J, Blass J. Depression in patients referred to a dementia clinic. Arch Neurol 1985;42:894-6.
73. Hachinski VC, Iliff LD, Zilhka E, Du Boulay HG, McAllister VL, Marshall J, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-7.
74. Jorm AF, van Duijn CM, Fratiglioni L, Graves AB, Heyman A, Kokmen E, et al. Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case control studies. Int J Epidemiol 1991;20(2 suppl):43S-47S.
75. Speck CE, Kukull WA, Brenner DE, Bowen JD, McCormick WC, Ten L. History of depression as a risk factor for Alzheimer's disease. Epidemiology 1995;6:366-9.
76. Van Duijn CM, Clayton DG, Chandra V, Fratiglioni L, Graves AB, Heyman A. Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. Genet Epidemiol 1994;11:539-51.
77. Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T. The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry 1993;150:1693-9.
78. Devanand DP, Sano M, Tang M-X, Taylor S, Gurland BJ, Wilder D, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996;53:175-82.
79. Alexopoulos GS, Young RC, Meyers BS. Geriatric depression: age of onset and dementia. Biol Psychiatry 1993;34:141-5.
80. Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Saunders AM, Breitner JCS. A twin study of late onset depression and apolipoprotein E ε4 as risk factors for Alzheimer's disease. Biol Psychiatry 1997;41:851-6.
81. Freedman M. Frontal and parietal lobe dysfunction in depression: delayed alternation and tactile learning deficits. Neuropsychologia 1994;32:1015-25.
82. Reynolds CF, Dew MA, Frank E, Begley AE, Miller MD, Cornes C. Effects of age of onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry 1998;155:795-9.
83. van Reekum R, Simard M, Clarke D, Binns MA, Conn D. Late-life depression as a possible predictor of dementia: cross-sectional and short-term follow-up results. Am J Geriatr Psychiatry 1999;7:151-9.
84. Hendrie HC. Epidemiology of dementia and Alzheimer's disease. Am J Geriatr Psychiatry 1998;6(2 Suppl 1):3S-18S
85. Brinton RD, Yamazaki RS. Advances and challenges in the prevention and treatment of Alzheimer's disease. Pharm Res 1998;15:386-98.
86. Rogers J, Webster S, Lue LF, Brachova L, Civin H, Emmerling M, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996;17:681-6.
87. McGeer PL, McGeer EG, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet 1990;335:1037.
88. Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin study. Neurology 1994,44:227-32.
89. Breitner JCS, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16:523-30.
90. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 1994;45:1441-5.
91. Rich JB, Rasmussen DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-5.
92. Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal anti-inflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-6.
93. Rozzini R, Ferrucci L, Losonczy K, Havlik RJ, Guralnik JM. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 1996;44:1025-9.
94. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
95. Prince M, Rabe-Hesketh S, Brennan P. Do antiarthritic drugs decrease the risk for cognitive decline? An analysi based on data from the MRC treatment trial of hypertension in older adults. Neurology 1998;50:374-9.
96. Rogers J, Kirby LC, Hempelman SR, Bery DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
97. Doraiswamy PM, Krishen A, Stallone F, Martin WL, Potts NLS, Metz A, et al. NSAIDs and cognition in Alzheimer's disease. Neurology 1996;46(4):1194.
98. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
99. He J, Whelton PK, Vu B, Klag M. Aspirin and risk of hemorrhagic stroke. A meta-analysi of randomized controlled trials. JAMA 1998;280:1930-5.
100. Fillit H. Future therapeutic developments of estrogen use. J Clin Pharmacol 1995;35(9 Suppl):25S-28S.
101. Wickelgren I. Estrogen stakes claim to cognition. Science 1997;276:675-8.
102. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Fich CE. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci 1998;18(9):3180-5.
103. Birge S. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc 1996;44:865-70.
104. Berlinger WG, Potter JF. Low body mass index in demented outpatients. J Am Geriatr Soc 1991;39:973-8.
105. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61.
106. Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker JC 3d. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol 1993;52: 135-42.
107. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156: 2213-7.
108. Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on aging. Neurology 1998; 50:996-1002.
109. Fillit H, Weinreb H, Cholst I, Luine V, McEwen B,Amador R, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-45.
110. Honjo H, Ogino Y, Naitoh K, Urabe M, Kitawaki J, Yasuda J, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989; 34:521-5.
111. Honjo H, Ogino Y, Naitoh K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: a placebo-controlled double blind study. J Jpn Menopause Soc 1993;1:167-71.
112. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994;41:361-71.
113. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-4.
114. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;27:985-91.
115. Lichtman R. Perimenopausal and postmenopausal hormone replacement therapy Part 1: an update of the literature on benefits and risks. J Nurse Midwifery 1996;41:3-28.
116. Whitehead M. Treatments for menopausal and postmenopausal problems: present and future. Baillieres Clin Obstet Gynaecol 1996;10(3):515-30.
117. Birge S. The role of estrogen in the treatment and prevention of dementia: introduction. Am J Med 1997;103(3A):1S-2S.
118. Gibaldi M. Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? J Clin Pharmacol 1997;37:1087-99.
119. McBee WL, Dailey ME, Dugan E, Shumaker SA. Hormone replacement therapy and other potential treatments for dementias. Endocrinol Metab Clin North Am 1997;26:329-45.
120. Johnson SR. Menopause and hormone replacement therapy. Med Clin North Am 1998;82:297-320.
121. Rodriguez MM, Grossberg GT. Estrogen as a psychotherapeutic agent. Clin Gerintr Med 1998;14:177-89.
122. Sherwin BB. Estrogenic effects on memory in women. Ann N Y Acad Sci 1994;743:213-30.
123. Shumaker S, Rapp S. Hormone replacement therapy in dementia prevention: the Women's Health Initiative memory study. Neurobiol Aging 1996;17(4 Suppl):S9.
124. Pincus MM. Alpha-tocopherol and Alzheimer's disease. N Eng J Med 1997; 337(8)572.
125. Kilander L, Ohrvall M. Alpha-tocopherol and Alzheimer's disease. New Eng J Med;1997;337(8):572.
126. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996;47:166-77.
127. Rogers SI, Friedhoff. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
128. Noble S, Wagstaff AJ. Propentofylline. Cent Nerv Syst Drugs 1997;8(3):257-64.